Enveda Biosciences, a Boulder, Colo.-based clinical-stage biotechnology company that uses AI to discover medicines from life's chemistry, closed a $311.0M Series E follow-on financing — its fifth institutional round and not a first-time raise. The round was led by Catalio Capital Management, with new investment from Durable Capital Partners, ICONIQ, Lightspeed, Surveyor Capital (a Citadel company), accounts advised by T. Rowe Price Investment Management, Digitalis Ventures, Alderline Group and a notable Sovereign Wealth Fund, alongside existing investors. The excerpt provided does not disclose specific operating metrics such as clients, revenue, pipeline candidates or employee count, nor a detailed planned use of proceeds or expansion plans.